DXC Technology Unveils DXC Bionix™ to Provide Automated IT Services at Scale
DXC Technology (NYSE: DXC), the world’s leading independent, end-to-end IT services company, today unveiled DXC Bionix™, a new digital-generation services delivery model that promises to provide a comprehensive approach to intelligent automation at the scale required by the world’s top companies.
DXC Bionix leverages analytics and AI, lean processes and leading automation capabilities to produce greater insight, speed and efficiency across the company’s global delivery ecosystem. DXC is leveraging DXC Bionix to respond to client demand for greater IT performance and the need to digitally transform traditional IT environments and processes.
For DXC’s global delivery operations, the performance gains from DXC Bionix have been impressive:
- 50 percent to 80 percent reduction in time spent on operations;
- 25 percent reduction in testing costs; 50 percent defect reduction; 60 percent reduction in testing time;
- reduction in average applications deployment time from 180 minutes to 15 minutes;
- a 65 percent reduction in business process transaction time with assisted Robotic Process Automation (RPA);
- 71 percent of incidents auto-resolved or auto-diagnosed without human intervention; and
- an 82 percent elimination of issues through rules-based filtering and alert correlation.
“Technology innovation and intelligent automation are rapidly changing the IT services business, and clients want to maximize performance and business outcomes from technology investments,” said Stephen Hilton, executive vice president, Global Delivery, DXC Technology. “By bringing smart industrial engineering into our delivery processes, we can work in a highly dynamic, repeatable and scalable way to deliver exceptional and transformative solutions to our clients.”
DXC Bionix uses real-time data collection and analysis to continuously measure and elevate performance. This helps the company, and ultimately its clients, make more informed decisions, eliminate waste, and produce more predictable results.
“We are also empowering our workforce by investing in our people, driving a cultural shift and elevating skillsets to ensure that DXC has the right digital-generation talent to optimally meet current and future clients’ needs,” Hilton noted. “For DXC, our partners and clients, DXC Bionix enables us to work smarter, faster and more efficiently—achieving new thresholds of quality and performance.”
Combining Analytics and AI, Lean Processes, and Intelligent Automation
DXC Bionix provides a complete, high-definition view of the IT services delivery operating environment to yield deeper learning and more useful information. The result is fewer business disruptions, reduced human error and operational risks and lower costs. And because it enables Straight Through Processing, DXC Bionix becomes a smart, fast, performance-driven and secure delivery engine that increases performance and agility across the enterprise.
There are three core elements of DXC Bionix:
- Analytics and AI to gain new, real-time insights into the business and operations including data mining, machine learning and predictive intelligence to identify and proactively address opportunities for reducing costs and delivering innovation;
- Lean processes to eliminate inefficiencies and continually improve solutions delivery, and optimize work flows and team performance for better quality, consistency and outcomes; and
- Leading Automation capabilities, leveraging best-of-breed technologies from the DXC partner network combined with DXC innovation, to automate tasks, processes and workflows and to improve response time, accuracy and standardization.
“The next decade will see the mass adoption of artificial intelligence, machine learning and robotics within IT services which will reduce the unit cost of implementation,” Hilton added. “However, it will bring complexity.
“The competitive advantage of innovation will only be realized by companies that can simplify and manage this dynamic end-to-end at massive scale and as-a-service. DXC Bionix and its underlying platforms are how DXC will be at the forefront of this change, providing a competitive advantage for the company, our clients and partners.”
“A 70 percent reduction in backend incidents through predictive analytics is, from my stand point, amazing,” said Damian Bunyan, CIO, Uniper. “This is backed up by a near 20 percent automation of the remaining workload. This feeds directly into your business case (which is important) and provides welcome stability to my business units. I dream of such predictive maintenance in my generation fleet!”
Platform DXC and Agile Process Automation
Underpinning DXC Bionix is Platform DXC, the company’s digital-generation delivery platform that provides an important foundation for future services delivery — including applications, business process services, cloud, data analytics, security, and workplace and mobility solutions. Platform DXC allows DXC to quickly build and deliver partner-engineered, at-scale, repeatable offerings and solutions that help drive client digital transformations.
DXC’s recently announced Agile Process Automation (APA) is a new digital platform and a DXC Bionix enabled solution that combines cloud and robotic process automation (RPA) with embedded artificial intelligence (AI) to enhance a company’s business processes.
"Most end-user organizations don't have a line item in their budgets for digital transformation, so DXC Bionix is welcome news because it will help DXC identify where cash can be freed up from existing IT operations and reapplied to fund its clients' digital transformations," said Gard Little, vice president, Global Services Markets and Trends, IDC.
For more information on DXC Bionix, and to view a video featuring Steve Hilton, visit www.dxcbionix.com.
About DXC Technology
DXC Technology (NYSE: DXC) is the world’s leading independent, end-to-end IT services company, helping clients harness the power of innovation to thrive on change. Created by the merger of CSC and the Enterprise Services business of Hewlett Packard Enterprise, DXC Technology serves nearly 6,000 private and public sector clients across 70 countries. The company’s technology independence, global talent and extensive partner network combine to deliver powerful next-generation IT services and solutions. DXC Technology is recognized among the best corporate citizens globally. For more information, visit www.dxc.technology.
Richard Adamonis, Corporate Media Relations
Donna Jenks, Corporate Media Relations
Jonathan Ford, Investor Relations
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28 | Pressemelding
Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (http://www.elektroniknet.de), a leading German electronics publication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005646/en/ Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05 | Pressemelding
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52 | Pressemelding
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50 | Pressemelding
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00 | Pressemelding
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on